Empiric Antibiotic Therapy for Gram-Negative Bacteremia

Initial Empiric Therapy Selection

The Infectious Diseases Society of America recommends empiric therapy with a fourth-generation cephalosporin, carbapenem, or β-lactam/β-lactamase combination, with or without an aminoglycoside, based on local antimicrobial susceptibility patterns and disease severity 1, 2
Selection of empiric therapy should be based on local antimicrobial susceptibility patterns, severity of illness, and patient risk factors, as recommended by the Infectious Diseases Society of America 1, 2
Adequate coverage of Pseudomonas aeruginosa is essential due to high mortality rates associated with this pathogen, according to the Infectious Diseases Society of America 3

For non-neutropenic patients, monotherapy options include fourth-generation cephalosporin (e.g., cefepime) 2, carbapenem (e.g., meropenem, imipenem-cilastatin) 1, 2, and β-lactam/β-lactamase inhibitor combination (e.g., piperacillin-tazobactam) 1, 2
Consider adding an aminoglycoside in cases of severe sepsis 4, critically ill patients 4, or high local prevalence of resistant organisms 1, 2

For suspected catheter-related bloodstream infections, empiric therapy should include coverage for gram-positive pathogens (vancomycin) and gram-negative bacilli, as recommended by the Infectious Diseases Society of America 1, 4
Consider broader coverage for patients with prior colonization with resistant organisms 1, recent antibiotic exposure 4, or local high prevalence of ESBL-producing Enterobacteriaceae 1, 2, 5

For uncomplicated gram-negative bacteremia with source control and clinical stability, 7 days of therapy may be sufficient, but 4-6 weeks of therapy is recommended for persistent bacteremia, complicated infections, or endocarditis, according to the Infectious Diseases Society of America 1, 2
Day 1 of therapy is considered the first day on which negative blood cultures are obtained, as defined by the Infectious Diseases Society of America 1, 2

Ignoring local resistance patterns can lead to inadequate empiric coverage, and local antimicrobial susceptibility data should guide empiric choices, as recommended by the Infectious Diseases Society of America 1, 2
Monotherapy in high-risk patients, such as severely ill patients with sepsis, neutropenic patients, or those known to be colonized with resistant pathogens, is not recommended, and combination therapy is preferred, according to the Infectious Diseases Society of America 1, 2

The American College of Oncology recommends combination therapy with an anti-pseudomonal β-lactam plus an aminoglycoside for high-risk patients, including those with severe sepsis or septic shock, neutropenia, or suspected Pseudomonas infection 6, 7, 8, 9
For less critically ill patients without risk factors for resistance, monotherapy with a broad-spectrum β-lactam is acceptable, according to the American College of Oncology 6, 7
The Infectious Diseases Society of America recommends carbapenems (meropenem, imipenem, or doripenem) for suspected ESBL-producing Enterobacteriaceae 10
The American College of Oncology suggests that ceftazidime resistance can develop during therapy, particularly with Pseudomonas, and recommends adding an aminoglycoside if clinical failure occurs 6, 8, 11

The American College of Oncology recommends achieving peak and trough bactericidal serum dilutions of at least 1:16 and 1:8 respectively for aminoglycosides 8, 9, 11
The Infectious Diseases Society of America advises against using short-course aminoglycosides for Pseudomonas, as inadequate aminoglycoside duration results in significantly worse outcomes compared to full-course therapy 6, 8

The American College of Oncology recommends against using ampicillin-sulbactam empirically due to high resistance rates among community-acquired E. coli 10
The Infectious Diseases Society of America advises against using cefotetan or clindamycin due to increasing resistance among Bacteroides fragilis group 10
The American College of Oncology recommends against using aminoglycoside monotherapy due to significant toxicity risk and inadequate empiric therapy 10
The Infectious Diseases Society of America emphasizes the importance of not delaying therapy for culture results, as gram-negative bacteremia can be rapidly fatal, and recommends initiating empiric therapy immediately while awaiting susceptibility data 6, 8, 9

Neutropenic patients have higher mortality and require broader coverage, according to the Journal of Clinical Oncology 12

The American Heart Association, as published in Circulation, recommends cefepime 2g IV every 8 hours PLUS gentamicin or tobramycin 5-7 mg/kg IV daily for high-risk patients 13
The American Heart Association, as published in Circulation, recommends piperacillin-tazobactam 4.5g IV every 6 hours PLUS gentamicin or tobramycin 5-7 mg/kg IV daily for high-risk patients 13
The American Heart Association, as published in Circulation, recommends meropenem 1-2g IV every 8 hours PLUS gentamicin or tobramycin 5-7 mg/kg IV daily for high-risk patients with ESBL-suspected cases 13
The Infectious Diseases Society of America, as published in Clinical Infectious Diseases, recommends meropenem 1-2g IV every 8 hours for ESBL-producing Enterobacteriaceae 14

The American Heart Association, as published in Circulation, recommends antipseudomonal beta-lactams, including cefepime, ceftazidime, piperacillin-tazobactam, and carbapenems, for adequate Pseudomonas coverage 13
The Infectious Diseases Society of America, as published in Clinical Infectious Diseases, recommends antipseudomonal beta-lactams, including aztreonam, for adequate Pseudomonas coverage 14

The American Heart Association, as published in Circulation, recommends gentamicin or tobramycin 5-7 mg/kg IV once daily, with monitoring of aminoglycoside levels in patients with renal impairment or prolonged therapy 13

The American Heart Association, as published in Circulation, recommends de-escalation to narrower-spectrum therapy based on culture results and susceptibility testing, and discontinuation of aminoglycoside after 3-5 days if patient is clinically stable 13